zn-c3
Small moleculeexperimental
Clinical trial activity
14 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
9
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2019 (NCT04158336)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Ovarian Epithelial · Phase 1/Phase 2
- Carcinoma, Transitional Cell · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 1
- Fallopian Tube Neoplasms · Phase 1/Phase 2
- Hamartoma · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Lung Neoplasms · Phase 1
- Melanoma · Phase 1/Phase 2
- Neoplasms · Phase 2
- Osteosarcoma · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 1
- Small Cell Lung Carcinoma · Phase 1/Phase 2
- Stomach Neoplasms · Phase 1
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
- Uterine Neoplasms · Phase 2
Mechanism of action
- Serine/threonine-protein kinase WEE1INHIBITOR
WEE1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C=CCn1c(=O)c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc2n1-c1ccc2c(n1)[C@@](O)(CC)CC2- Mol. weight
- 526.65 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095036 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06364410 | Phase 1 | Jul 7, 2025 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT06369155 | Phase 2 | Jan 1, 2025 | Harvard University, National Cancer Institute (NCI) |
| NCT06351332 | Phase 1/Phase 2 (Phase 2) | May 1, 2024 | Harvard University, Merck, Zentalis Pharmaceuticals |
| NCT05743036 | Phase 1/Phase 2 (Phase 2) | Feb 27, 2023 | Pfizer, Zentalis Pharmaceuticals |
| NCT05368506 | Early Phase 1 (Phase 1) | Dec 30, 2022 | OHSU Knight Cancer Institute, Oregon Health and Science University |
| NCT05431582 | Phase 1 | Dec 14, 2022 | University of Texas at Houston, Zentalis Pharmaceuticals |
| NCT05682170 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2022 | K-Group Beta, Zentalis Pharmaceuticals |
| NCT05198804 | Phase 1/Phase 2 (Phase 2) | Jan 27, 2022 | K-Group Beta |
| NCT05128825 | Phase 2 | Dec 1, 2021 | K-Group Beta |
| NCT04833582 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2021 | K-Group Beta |
| NCT04972422 | Phase 1 | Jul 15, 2021 | Zentera Therapeutics HK Limited |
| NCT04814108 | Phase 2 | Jun 1, 2021 | K-Group Beta |
| NCT04516447 | Phase 1 | Oct 26, 2020 | K-Group Beta |
| NCT04158336 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2019 | IQVIA, K-Group Beta |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| K-Group Beta | For profit | 7 | 6 | 2 | 2019 |
| Zentalis Pharmaceuticals | For profit | 4 | 2 | 2 | 2022 |
| Harvard University | Academic/Hospital | 2 | 2 | 1 | 2024 |
| National Cancer Institute (NCI) | Government | 2 | 1 | 2 | 2025 |
| University of Texas at Houston | Academic/Hospital | 2 | 1 | 1 | 2022 |
| IQVIA | For profit | 1 | 0 | 1 | 2019 |
| Merck | For profit | 1 | 0 | 1 | 2024 |
| OHSU Knight Cancer Institute | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Oregon Health and Science University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Pfizer | For profit | 1 | 0 | 1 | 2023 |
| Zentera Therapeutics HK Limited | For profit | 1 | 1 | 1 | 2021 |
11 organizations
Page 1 / 1